Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million on September 19, 2022. Under the terms of transaction, Genfit S.A. will pay initial consideration of CHF 40 million due at closing, with contingent consideration of up to CHF 65 million upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. In addition, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the Pediatric Review Voucher of VS-01's pediatric application by GENFIT to a third party, or 1/3 of the fair market value of this Voucher if GENFIT opts to apply it to one of its own programs. GENFIT will finance the base acquisition consideration from its current cash and cash equivalents. The deal is subject to completion of the consultation of GENFIT's employees representative bodies and is expected to be completed during the fourth quarter 2022, Torreya Capital, LLC acted as financial advisor to Versantis AG. Goodwin Procter LLP acted as legal advisor to the sellers of Versantis AG. VISCHER AG acted as legal advisor to Versantis AG. Pierre Thomet, Julien Bourmaud-Danto, Gabriel Grossman, Thomas Elkins, Andrew Gaines, Pierre-Emmanuel Perais, Bertrand Sénéchal, Sterling Darling and Géric Clomes of Linklaters LLP acted as legal advisor to Genfit S.A. (ENXTPA:GNFT). Philipp Haas, Daniela Schmucki, Ulysses von Salis, Christina Rinne and Andreas Casutt of Niederer Kraft Frey acted as legal advisors to Genfit S.A.

Genfit S.A. (ENXTPA:GNFT) completed the acquisition of Versantis AG on September 29, 2022.